Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Trust iShares Russell 2000 BuyWrite ETF (NY:IWMW)

38.38 -0.67 (-1.72%)
Official Closing Price Updated: 4:10 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Trust iShares Russell 2000 BuyWrite ETF

CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock
The company is now poised to initiate late-stage trials for Neflamapimod. 
Via Stocktwits
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why
Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.” 
Via Stocktwits
Topics Death
Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued
Via Stocktwits
Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price
Via Stocktwits
Joby Aviation Stock Flies High On Expansion Of Marina Site, Retail Boards The Flight
Once fully operational, the expanded Marina site is expected to be capable of producing up to 24 aircraft per year, or nearly one every other week. 
Via Stocktwits
Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy
The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and... 
Via Stocktwits
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. 
Via Stocktwits
Topics Government
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous... 
Via Stocktwits
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up... 
Via Stocktwits
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.